Physician Inattention To Drug Labeling Influencing FDA Risk/Benefit Analyses
Executive Summary
Lack of prescriber compliance with drug labeling is beginning to influence FDA's risk/benefit analyses, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, told an FDA/industry conference at Temple University in Philadelphia April 4.